ArticleFrontiers in cardiovascular medicine2026
Fatigue after pulmonary embolism-prevalence and predictors.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary embolism (PE) is a common condition with negative long-term consequences such as reduced quality of life. However, there is little knowledge regarding fatigue after PE. The aim of this study was to determine prevalence and predictors of fatigue after PE. Methods: The Lungenembolie Augsburg (LEA) study includes patients treated for acute PE at the University Hospital of Augsburg, Germany. Patients were interviewed during hospitalization and received postal questionnaires after 3 and 12 months. Fatigue was assessed using the Fatigue Assessment Scale (FAS). Data from the "Stroke Cohort Augsburg (SCHANA)" study and the "Metabolism, Nutrition and Immune System in Augsburg (MEIA)" study were used to compare fatigue prevalence after PE with that after stroke and in the general population. Multiple linear regression models were built to identify baseline predictors for fatigue 3 and 12 months after PE. Results: Three months after PE, the age-sex-standardized fatigue prevalence was 40.76% [95% confidence interval (CI): 24.81%-56.71%] and 12 months after PE it was 32.36% (95% CI: 20.72%-44.01%), which was significantly higher than in the general population (12.68%; 95% CI: 9.75%-15.61%), but did not significantly differ from the prevalences found in patients with stroke (3 months: 30.97% (95% CI: 22.73%-39.22%); 12 months: 28.02% (95% CI: 17.49%-38.55%). Multiple linear regression models revealed that gender modified the relationship between depression at baseline and fatigue 3 and 12 months after PE. In men, Hospital Anxiety and Depression Scale (HADS) Depression score ( Discussion: The results show that fatigue is common after PE. Early screening for depression and fatigue in both men and women should be considered. Lower school education level in men was shown to be a predictor of fatigue and should be taken into account when screening patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.